Quest Diagnostics is expanding its business line to give precision oncology services medicine diagnostics to aid oncologists in giving optimized cancer treatment and care for patients.
Madison, N.J.-based Quest is utilizing the acquisition of two lab businesses–Med Fusion and Clear Point–in Texas to form the basis for a precision oncology services center of excellence. The two labs give a complete range of diagnostic services to physicians and provider networks.
With the acquisitions, Quest will become a preferred provider of advanced oncology diagnostics for The US Oncology Network, which involves Texas Oncology. The US Oncology Network, which is supported by McKesson Specialty Health, a division of McKesson, contains more than 400 locations across the U.S. and more than 1,400 independent community-based physicians.
Quest targets to form a new precision oncology center of excellence that intends to give community oncologists with insights on tracing cancer in sufferers and managing their care.
Quest will give genomic and pathology testing, tumor sequencing and other advanced diagnostics to choose and monitor treatment and predict disease progression.
“Precision medicine is changing the way we treat cancer and offering new hope to people living with the disease, but too often, advanced diagnostics that facilitate the best possible care are out of reach of community oncologists and their sufferers,” claimed Steve Rusckowski, chairman, president and CEO, Quest Diagnostics. “By partnering with McKesson Specialty Health and The Network, we will make Quest’s state-of-the-art genomic analysis readily available to community oncologists everywhere.”
The transaction is anticipated to be completed in the third quarter of calendar year 2017, subject to the satisfaction of customary closing conditions, involving obtaining required regulatory approvals. Additional terms weren’t unveiled.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment